INTRODUCTION
Behçet's disease (BD) is a chronic recurring multisystemic vasculitic disorder involving recurrent oral ulcers; genital ulcers; ocular lesions; skin manifestations; arthritis; and vascular, neurologic, and intestinal involvement. 1, 2 Intestinal BD is diagnosed when a patient with BD has both dominant gastrointestinal symptoms and typical intestinal ulcerative lesions on objective examinations. 3 The intestinal involvement of BD is rare, ranging 5% to 20%, and it is more prevalent in East Asian countries, including Korea and Japan. 4 Typical intestinal ulceration of intestinal BD is oval in shape and deep with discrete border located in the ileocecal area. 5 It can cause diarrhea, abdominal pain, gastrointestinal bleeding, or bowel perforation. 6, 7 Intestinal BD has a heterogeneous range of clinical courses and symptoms, and a gold standard therapy remains elusive. Research on intestinal BD is relatively scarce because of the rarity of this disease. 8 Moreover, intestinal BD is often refractory to conventional treatment such as corticosteroids and immunomodulators; therefore, alternative therapies are needed. 9 Currently, anti-tumor necrosis factor-α (anti-TNF-α), a potential therapeutic strategy, is being evaluated, and evidence for its effectiveness has been accumulating. In Japan, anti-TNF-α has received approval to be used for the treatment of intestinal BD in cases where existing treatments are inadequate. 10, 11 One TNF-α receptor fusion protein (etanercept), three anti-TNF-α monoclonal antibodies (infliximab, adalimumab, and golimumab), and one anti-TNF-α PEGylated antigen-binding fragment (certolizumab pegol) are currently approved as anti-TNF-α therapies for several immune-mediated disorders. 12 This article reviews the progress in the management of intestinal BD, focusing on current anti-TNF-α usage and possible future perspectives.
PATHOGENESIS
The pathogenesis of intestinal BD is still unclear; in addition to genetic factors, immune dysfunction and multiple cytokines are associated with the development and progression of disease. 13 Several data suggest a role of TNF-α in the pathogenesis of intestinal BD. Inflammation in intestinal BD is thought to be mediated by cytokines derived from T helper type 1 (Th1) lymphocytes, including TNF-α. 14 T cells at the intestinal mucosal level produce a large concentration of TNF-α, and T cells induce inflammation leading to mucosal damage through abnormal cytokine production, especially during the active phase of the disease. 15, 16 Recently, Emmi et al. 17 reported that in the early stages of intestinal BD, both Th1 and Th17 cells produce a large amount of TNF-α. In the colonic tissue of patients with BD, interferon-γ (IFN-γ), TNF-α, and interleukin-17A (IL-17A) appeared to be key cytokines, even in a treated patient. 18 Misumi et al. 19 reported that anti-TNF-α treatment induced a significant increase in the number of cells secreting IFN-γ and expressing IL-12Rβ1. The increasing number of IFN-γ producing cells in BD patients treated with infliximab means that anti-TNF-α could modulate the functional activity of T cells. TNF-α is also produced by γδT cells, and infliximab is capable of interfering with Vγ9/Vδ2T cell function in BD. 20 The regulation of γδT cells by anti-TNF-α might play an important role in the treatment of intestinal BD. Sugita et al. 21, 22 demonstrated that anti-TNF-α treatment induced the development of regulator T cells in patients with uveitis and BD. Therefore, blocking TNF-α function with anti-TNF-α and subsequent suppression of γδT cell expansion and activation is currently a potential therapeutic strategy.
ANTI-TNF AGENTS IN INTESTINAL BEHÇET'S DISEASE:
THE CURRENT EVIDENCE
Infliximab
Infliximab is a chimeric monoclonal antibody biologic drug that was first demonstrated in 2001 as an effective new therapy for patients with steroid-dependent intestinal BD. 23 Infliximab is currently one of the most frequently described biologic agents for patients with intestinal BD. Infliximab was infused at 0, 2, and 6 weeks and every 8 weeks thereafter at 3-5 mg/kg in most studies (Table 1) . [24] [25] [26] [27] [28] [29] [30] Hassard et al. 23 reported that a patient treated with four doses of infliximab over a period of 6 months had improvement in gastrointestinal symptoms and extraintestinal symptoms, a decreased Crohn's Disease Activity Index at week 2, and marked endoscopic and histological improvement at week 10. Travis et al. 31 used infliximab to induce remission in two patients with refractory intestinal BD (dose reduced to 3 mg/kg because of recent sepsis in one patient, and 5 mg/kg in the other). The ulcers healed with resolution of hematochezia and extraintestinal symptoms within 10 days, and remission was initially sustained for 12 months. Kram et al. 32 reported that a patient treated with two doses of 5 mg/kg infliximab revealed ulcer healing and normalized erythrocyte sedimentation rate and C-reactive protein (CRP) levels. Clinical remission of intestinal BD after infliximab has been described in several case reports. [33] [34] [35] [36] [37] Combination therapy of infliximab and methotrexate was administered to 10 Japanese patients with refractory intestinal BD who failed to respond to conventional therapy, and it provided short-and long-term efficacy and tolerability as assessed by abdominal computed tomography (CT) and colonoscopy. 24 Intestinal manifestations, including tenderness and bleeding, disappeared within 3 months, and improvement was confirmed at only 2 weeks after the initiation of infliximab infusions in all seven patients assessed on abdominal CT. Ileocecal ulceration disappeared in five patients (50%) at 6 months and nine patients (90%) at 12 months, as confirmed by colonoscopy. In a multicenter retrospective study, the primary outcome was reported using the disease activity index of intestinal Behçet's disease (DAIBD) score with 28 Korean patients with moderate to severe intestinal BD. 25 ). Participants will receive infliximab 5 mg/kg infusion at weeks 0, 2, and 6 for the induction phase and after that every 8 weeks until week 32 in the maintenance phase. The mean decrease in DAIBD scores of 20 or more will be evaluated primarily, and adverse events will be monitored throughout the study.
Adalimumab
Adalimumab is a completely humanized IgG1 monoclonal anti-TNF-α antibody which could bind to TNF-α and prevent it from binding to its receptors. It was the third TNF-α inhibitor approved by the U.S. Food and Drug Administration (FDA), after infliximab and etanercept. Adalimumab has been approved for indications including juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), hidradenitis suppurativa, psoriasis, and panuveitis. 39 It was recently approved and recommended as a standard therapy for intestinal BD in Japan, Taiwan, and South Korea. 11, 40 There are few available reports regarding adalimumab efficacy for intestinal BD (Table 2) . [41] [42] [43] [44] In 2007, van Laar et al. 45 reported the first case series presenting patients with BD with systemic disease treated with adalimumab. One patient was diagnosed with intestinal BD and was treated with infliximab and other immunosuppressive agents for nearly 3 years. A high dose of adalimumab, 40 mg/week, was administered subcutaneously for refractory and life-threating intestinal BD, and the patient achieved complete response and remained stable for nearly 2 years. In 2011, De Cassan et al. 46 presented the first case of adalimumab administered as the first anti-TNF-α in a patient with intestinal BD. Two siblings with mucocutaneous ulcerations and ileocolitis received adalimumab at an induction dose of 80 mg subcutaneously, followed by 40 mg 2 weeks later and a maintenance schedule of 40 mg every other week. Both clinical response and complete remission were achieved stable after induction therapy, allowing corticosteroid-free remission for nearly 1 year. There was a case report about the efficacy of adalimumab with combined hematologic disorders. Generally, patients with intestinal BD with myelodysplastic syndrome (MDS) involving trisomy 8 are refractory to conventional medical therapies and infliximab. 47 Kimura et al. 48 demonstrated a favorable effect of adalimumab in patients with refractory intestinal BD and in those with MDS involving trisomy 8.
The relationship between adalimumab and pathologic finding has also been studied. Mizoshita et al. 49 43 followed up these patients and evaluated the long-term safety profile and effectiveness of adalimumab through 100 weeks in patients rolled over from a 52 week-clinical trial. At weeks 52 and 100, 60% and 40% of patients showed clinical response, and 20% and 15% of patients showed complete remission, respectively. The overall incidence of adverse events during the study was comparable to that in other studies investigating patients with inflammatory bowel diseases. Combination therapy of adalimumab with disease-modifying antirheumatic drugs does not appear to be significantly superior to adalimumab monotherapy. 44 There were no differences between monotherapy and combination therapy in terms of efficacy, time to response, relapses, and adalimumab discontinuation in 100 consecutive patients with BD over a period of 24 months. Moreover, the frequency and time to response for adalimumab were not associated with a previous loss of response of other anti-TNF-α agents. Conversely, the relapse frequency and adalimumab discontinuation at the 2-month follow-up evaluation were significantly higher among patients that had previously experienced failure of an anti-TNF-α agent. A prospective, multicenter clinical study on adalimumab lasting up to 50 weeks in Japanese patients with BD (NCT01243671) has been completed but has not yet been published. A prospective, open-label, single-arm, phase 3, multicenter clinical trial of adalimumab in Korean patients with intestinal BD is recruiting participants (ClinicalTrials.gov, NCT 02687828). Once these two studies are completed, further evidence for adalimumab in intestinal BD will be established.
Etanercept
Etanercept is a dimeric humanized anti-TNF-α antibody, manufactured by recombinant DNA techniques, has a greater binding affinity by the combination of two naturally occurring soluble human TNF receptors linked to the Fc portion of an IgG1. 50 Etanercept has been approved for indications including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis but not for inflammatory bowel diseases. Etanercept has proved to be effective in controlling intestinal BD with a good safety profile (Table 3) . [51] [52] [53] Watanabe et al. 54 reported the case of one 
Golimumab
Golimumab is created with genetically engineered mice immunized with human TNF, resulting in the expression of fully humanized antibodies. 61 Golimumab is approved for the treatment of UC by the U.S. FDA in 2013. Only a few data are available on golimumab in patients with intestinal BD (Table 3) . Vitale et al. 52 retrospectively assessed the long-term efficacy and safety of golimumab in patients with intestinal BD. The BD Current Activity Form (BDCAF) was used to evaluate disease activity in this study. Of 17 patients, six patients were administered golimumab for gastrointestinal involvement. All patients in the study underwent golimumab therapy for poorly controlled disease despite previously undergoing conventional treatment and after the failure of at least one or more biologic agents. BD manifestations disappeared after a mean of 5 weeks, and 12 patients still continued the treatment after a mean of 18 months. Notably, combination therapy of golimumab with DMARDs resulted in better outcomes as compared to golimumab monotherapy. Golimumab could be an effective therapy agent for patients with intestinal BD. However, further studies on wider populations need to be conducted to draw a conclusion about the effectiveness of golimumab for intestinal involvement of BD.
Certolizumab pegol
Certolizumab pegol is the only PEGylated anti-TNF-α biologic approved for the treatment of rheumatoid arthritis and CD. It is a humanized antigen-binding fragment of a monoclonal antibody which is conjugated to polyethylene glycol. Data about therapy with certolizumab pegol for BD are scarce (Table 3) . Lopalco et al. 53 reported treatment with certolizumab pegol for 13 patients with BD who were refractory to standardized therapies and previous biologic agents. The 13 patients had involvement of different organs, and five patients started certolizumab for intestinal involvement of BD. Certolizumab was treated at an induction dose of 400 mg at 0, 2, and 4 weeks, followed by 200 mg every 2 weeks. Of the 13 patients, seven patients (53.84%) experienced a satisfactory response at the last follow-up visit (mean, 9.28 months). The mean BDCAF score was decreased, but this did not reach statistical significance (p=0.51). Further studies enrolling a larger number of patients are needed to validate the effectiveness of certolizumab pegol for patients with intestinal BD.
ANTI-TNF AGENTS IN INTESTINAL BEHÇET'S DISEASE: SAFETY ISSUES
Current knowledge about the complications of anti-TNF-α agents is mostly based on controlled clinical trials in treating IBD or rheumatoid diseases. Data derived from studies of their use for intestinal BD are scarce. Table 4 shows the complications associated with anti-TNF-α agents in recent studies including more than 10 patients with intestinal BD. There were no malignancies in these studies. There were some serious infections and infusion reactions, and tuberculosis was observed in one Japanese patient. 41 Lee et al. 25 reported one gastrointestinal sepsis requiring surgical resection after 16 weeks of infliximab therapy. Zou et al. 30 reported one case of severe pneumonia requiring hospitalization in a patient treated with infliximab. Inoue et al. 43 reported three serious infections, including intestinal abscess, appendicitis, and perforated appendicitis in patients treated with adalimumab. Theoretically, inhibiting TNF could reduce the immunity of host system to increase a proper defense against infectious organisms. Although the benefits of TNF inhibitor therapy are amendable, concerns have been raised about the risk of infectious and malignant complications. 62 Although the risk of lymphoma is an important concern associated with therapy for IBD, there are limited data on the risk of non-Hodgkin's lymphoma (NHL) among anti-TNF-α agent users in IBD. 63 The standardized incidence ratio (SIR) of NHL was 3.23 (95% confidence interval [CI], 1.5 to 6.9) in a previous meta-analysis that involved a majority of patients using 66 Intestinal BD is the most common along the ancient "Silk Road" route in the Far East and in the Mediterranean basin, and the prevalence of lymphoma and skin cancer is very low in this area. 67 Current guidelines for malignancy in
Asian patients with IBD focus on the surveillance of colorectal cancer. 40 Patients with IBD are at increased risk for overall, intestinal, and hematological cancer. 68 Likewise, intestinal BD is frequently associated with bone marrow disorders such as MDS and aplastic anemia. 69 Therefore, close monitoring and identification of individual risk factors for malignancy is an important principle in biologic therapy for intestinal BD.
In terms of infection, analyses of infliximab safety data indicated no increase in infections during infliximab therapy in patients with CD or UC. 70 The proportion of patients who experienced a serious infection was similar between infliximab group and the placebo group in five pivotal phase 3 IBD trials (ACCENT I, ACCENT II, SONIC, ACT 1, and ACT 2). A larger proportion of patients with UC, not CD, treated with infliximab with immunomodulator had at least one infection compared to the no immunomodulator treatment group. Especially, tuberculosis and viral hepatitis are endemic in East Asian countries. In a multicenter, observational Korean study, the adjusted SIR of tuberculosis was 41.7 (95% CI, 25.3 to 58.0), compared with that of the matched general population. 71 Present or past hepatitis B infection was found in 40.62% of patients with IBD and in 27.58% of the patients without IBD in a Chinese study (p<0.001). 72 Previous examination and vaccination before the use of anti-TNF-α and continuous evaluation for tuberculosis and hepatitis in patients with intestinal BD are mandatory.
SUMMARY AND FUTURE DIRECTION
Intestinal BD is a chronic, relapsing inflammatory disease that is associated with a severe disease course, such as perforation and bleeding. Many patients fail to respond to conventional treatments with corticosteroids and immunomodulatory agents, including thiopurines. Although the clinical remission rate at 1 month to corticosteroid therapy in intestinal BD was high, the response showed a decreasing at 1 year (46.3% vs 35.2%). 10 Moreover, the cumulative relapse rates at 1, 2, 3, and 5 years were 5.8%, 28.7%, 43.7%, and 51.7% in patients with intestinal BD who received thiopurine therapy, respectively. 73 Currently, anti-TNF-α agent therapy has demonstrated significantly favorable outcomes in patients with intestinal BD who are refractory to or intolerant to conventional therapy. Therefore, anti-TNF use will be gaining more popularity in terms of intestinal BD management in the near future. Its indications will also be more broadened. However, additional studies of larger cohorts of patients are needed to clarify the rationale underlying the outcomes observed in each of the previous small studies. Additionally, possible complications including infection, vaccination, and malignancy surveillance should be considered during biologic therapy for intestinal BD. It has not yet been determined if vedolizumab, a novel anti-integrin therapy for the treatment of IBD, could be a promising alternative therapeutic option for patients with intractable intestinal BD.
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